Abstract
Adoptive T cell therapies can produce objective clinical responses in patients with hematologic and solid malignancies. Genetic manipulation of T lymphocytes has been proposed as a means of increasing the potency and range of this anti-tumor activity. We now review how coupling expression of transgenic receptors with countermeasures against potent tumor immune evasion strategies is proving highly effective in pre-clinical models and describe how these approaches are being evaluated in human subjects.
Original language | English (US) |
---|---|
Pages (from-to) | 396-408 |
Number of pages | 13 |
Journal | Current Gene Therapy |
Volume | 9 |
Issue number | 5 |
DOIs | |
State | Published - 2009 |
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Genetics
- Drug Discovery
- Genetics(clinical)